Next generation sequencing (NGS) has become a routine component in oncology diagnostics. As a result NGS data volumes are growing exponentially. Through its clinical decision support software and services, QIAGEN is uniquely positioned to integrate and analyze this data in the context of other data to help guide drug development and clinical trials. Through illustration of industry relevant use cases this webinar will explore the utility of QIAGEN’s large and diverse molecular database and its value for decision making across the drug development lifecycle.
Speaker: Sheryl Elkin, Ph.D., Chief Scientific Officer, QIAGEN Digital Insights
Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. Dr. Elkin joined QIAGEN through the acquisition of N-of-One, and has led a team interpreting thousands of patient cases, establishing a rigorous process for analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians. Dr. Elkin played a lead role in the development of the N-of-One clinical interpretation methodology that supports clinicians in identifying therapeutic strategies for patients and has been a key player in the integration of N-of-One with the QIAGEN Clinical Insights software. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude.